Equities Analysts Offer Predictions for RXi Pharmaceuticals Corp’s FY2018 Earnings (RXII)

RXi Pharmaceuticals Corp (NASDAQ:RXII) – Zacks Investment Research upped their FY2018 earnings estimates for shares of RXi Pharmaceuticals in a research report issued to clients and investors on Thursday, October 4th. Zacks Investment Research analyst J. Vandermosten now expects that the biotechnology company will earn ($1.96) per share for the year, up from their prior forecast of ($2.40). Zacks Investment Research also issued estimates for RXi Pharmaceuticals’ Q4 2018 earnings at ($0.09) EPS, FY2019 earnings at ($0.44) EPS and FY2020 earnings at ($0.48) EPS.

RXi Pharmaceuticals (NASDAQ:RXII) last announced its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.16. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.02 million.

A number of other brokerages have also issued reports on RXII. HC Wainwright set a $3.00 price target on RXi Pharmaceuticals and gave the company a “buy” rating in a report on Monday, July 16th. ValuEngine upgraded RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd.

Shares of NASDAQ RXII opened at $0.63 on Monday. The company has a market capitalization of $5.12 million, a P/E ratio of -0.15 and a beta of 1.29. RXi Pharmaceuticals has a 52-week low of $0.55 and a 52-week high of $7.70.

An institutional investor recently bought a new position in RXi Pharmaceuticals stock. SG Americas Securities LLC purchased a new stake in RXi Pharmaceuticals Corp (NASDAQ:RXII) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000. SG Americas Securities LLC owned 2.78% of RXi Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 8.87% of the company’s stock.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Further Reading: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply